Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors
Overview
Authors
Affiliations
Purpose: To assess the feasibility and early results of online adaptive MR-guided radiotherapy (oMRgRT) of liver tumors.
Methods: We retrospectively examined consecutive patients with primary or secondary liver lesions treated at our institution using a 0.35T hybrid MR-Linac (Viewray Inc., Mountain View, CA, USA). Online-adaptive treatment planning was used to account for interfractional anatomical changes, and real-time intrafractional motion management using online 2D cine MRI was performed using a respiratory gating approach. Treatment response and toxicity were assessed during follow-up.
Results: Eleven patients and a total of 15 lesions were evaluated. Histologies included cholangiocarcinomas and metastases of neuroendocrine tumors, colorectal carcinomas, sarcomas and a gastrointestinal stroma tumor. The median BED of the PTV prescription doses was 84.4 Gy (range 59.5-112.5 Gy) applied in 3-5 fractions and the mean GTV BED was in median 147.9 Gy (range 71.7-200.5 Gy). Online plan adaptation was performed in 98% of fractions. The median overall treatment duration was 53 min. The treatment was feasible and successfully completed in all patients. After a median follow-up of five months, no local failure occurred and no ≥ grade two toxicity was observed. OMRgRT resulted in better PTV coverage and fewer OAR constraint violations.
Conclusion: Early results of MR-linac based oMRgRT for the primary and secondary liver tumors are promising. The treatment was feasible in all cases and well tolerated with minimal toxicity. The technique should be compared to conventional SBRT in further studies to assess the advantages of the technique.
MR-linac: role of artificial intelligence and automation.
Psoroulas S, Paunoiu A, Corradini S, Horner-Rieber J, Tanadini-Lang S Strahlenther Onkol. 2025; 201(3):298-305.
PMID: 39843783 PMC: 11839841. DOI: 10.1007/s00066-024-02358-9.
MR-linac based radiation therapy in gastrointestinal cancers: a narrative review.
Ristau J, Horner-Rieber J, Korber S J Gastrointest Oncol. 2024; 15(4):1893-1907.
PMID: 39279945 PMC: 11399841. DOI: 10.21037/jgo-22-961.
Buchele C, Renkamp C, Regnery S, Behnisch R, Rippke C, Schluter F Radiat Oncol. 2024; 19(1):80.
PMID: 38918828 PMC: 11202341. DOI: 10.1186/s13014-024-02466-x.
Gupta A, McQuaid D, Dunlop A, Barnes H, Mohajer J, Smith G Adv Radiat Oncol. 2024; 9(6):101490.
PMID: 38681895 PMC: 11046225. DOI: 10.1016/j.adro.2024.101490.
Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data.
Shouman M, Fuchs F, Walter F, Corradini S, Westphalen C, Vornhulz M Clin Transl Radiat Oncol. 2024; 45:100738.
PMID: 38370495 PMC: 10873666. DOI: 10.1016/j.ctro.2024.100738.